Feifel David, Shilling Paul D, MacDonald Kai
Department of Psychiatry, University of California, San Diego, La Jolla, California.
Department of Psychiatry, University of California, San Diego, La Jolla, California.
Biol Psychiatry. 2016 Feb 1;79(3):222-33. doi: 10.1016/j.biopsych.2015.07.025. Epub 2015 Aug 13.
Schizophrenia is a disabling, heterogeneous disorder with clinical features that can be parsed into three domains: positive symptoms, negative symptoms, and cognitive deficits. Current antipsychotic drugs produce fairly robust clinical benefit against positive symptoms but typically have minimal therapeutic effects on negative symptoms and cognitive deficits. Oxytocin (OT) is a nonapeptide that, in addition to its role as a hormone regulating peripheral reproductive-relevant functions, acts as a neurotransmitter in the brain. Several lines of preclinical and clinical research suggest that the OT system may play a role in regulating the expression of schizophrenia spectrum disorders and that targeting the central OT system may yield novel treatments to address these symptoms. In this review, we summarize the extant preclinical and clinical evidence relevant to the role of OT in schizophrenia with particular emphasis on its putative therapeutic effects on each of the three above-mentioned clinical domains.
精神分裂症是一种致残性的异质性疾病，其临床特征可分为三个领域：阳性症状、阴性症状和认知缺陷。目前的抗精神病药物对阳性症状有相当显著的临床疗效，但对阴性症状和认知缺陷通常治疗效果甚微。催产素（OT）是一种九肽，除了作为调节外周生殖相关功能的激素发挥作用外，还在大脑中充当神经递质。多项临床前和临床研究表明，OT系统可能在调节精神分裂症谱系障碍的表达中发挥作用，针对中枢OT系统可能会产生新的治疗方法来解决这些症状。在本综述中，我们总结了与OT在精神分裂症中的作用相关的现有临床前和临床证据，特别强调其对上述三个临床领域中每个领域的假定治疗效果。
